BioCentury on BioBusiness,
Product Discovery & Development
Amgen, Regeneron PCSK9s look similar so far, but more data in LDL due this year
Related tables, figures and sidebars
Monday, April 14, 2014
The early Phase III data appear similar for competing
anti-PCSK9 mAbs from Amgen
Inc. on one end and partners Regeneron
Pharmaceuticals Inc. and Sanofi
on the other. But starting mid-year, additional data in the populations where
PCSK9 inhibitors are most likely to be used - familial hypercholesterolemia or
statin intolerance - should begin to provide a better view on how the mAbs will
convertase subtilisin/kexin 9 reduces LDL-C by preventing the protein from
enhancing the degradation of LDL receptors that clear LDL from the circulation.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]